News & Events
Published On: 12/18/2020
Target RWE Virtual Posters at Annual AIBD, RAD Conferences
In December, Target RWE participated in two virtual conference events to highlight accepted abstract posters- Advances in Inflammatory Bowel Disease (AIBD) and Revolutionizing Atopic Dermatitis (RAD) Conference. The accepted abstract posters highlighted details and information from the ongoing Target RWE observational studies, TARGET-IBD and TARGET-DERM.
The TARGET-IBD poster accepted to AIBD titled ‘Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD’ focuses on better understanding patterns of treatment discontinuation in real-world management of patients with inflammatory bowel disease (IBD). The analysis found that nearly 1/3 of the TARGET-IBD patients initiating biologic therapy discontinued this therapy during the course of observation (mean time to discontinuation was 383 days). The most common reasons for discontinuation were:
- Secondary loss of response
- Side effects
- Primary non-response
The Target RWE poster accepted to the RAD Conference titled ‘International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale’ describes the importance of the international TARGET-DERM cohort of atopic dermatitis (AD) patients with the primary aims of:
- Characterization of AD treatment regimens
- Evaluation of response to therapy, and
- Description of adverse events
“The work presented at AIBD included several important findings while the poster presented at RAD described the TARGET-DERM methodology; each conference is a terrific, disease-specific setting for sharing this information,” said Julie M. Crawford, MD, Senior Director of Scientific and Medical Affairs.
Both Target RWE posters are in the process or have moved to manuscript next, with the TARGET-DERM methodology manuscript recently published with BMJ Open. You can find both posters on our Publications page.
About Target RWE
Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.
Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe and other non-U.S. locations. Target RWE’s datasets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases. Whether partners need consulting services, datasets, support for custom solutions or access to a large biorepository of disease agnostic patient samples, Target RWE strives to be the preferred choice.
For more information, visit www.targetrwe.com.
984.234.0268 ext 205
01/15/2021Target RWE Acquires NoviSci Inc., Adding Significant Analytical Capabilities to Leading Real-World Evidence Platform
12/21/2020TARGET-HCC Initial Manuscript Published in Hepatology Communications
12/18/2020Target RWE Virtual Posters at Annual AIBD, RAD Conferences
11/28/2020TARGET-DERM Objectives Published in BMJ Open
11/13/2020Target RWE Data Presented at AASLD Virtual Meeting Provides Important Updates for NASH and PBC Communities